Erlotinib vs Ipilimumab

Erlotinib vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Erlotinib and Ipilimumab.

Mechanism of Action

Erlotinib: Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Erlotinib — 36 hours; Ipilimumab — 14.7 days.

Chemical Properties

Molecular Formula: Erlotinib — C22H23N3O4.

Molecular Weight: Erlotinib — 393.4380 g/mol.

Type: Erlotinib — Small molecule; Ipilimumab — Antibody.